229 related articles for article (PubMed ID: 15156186)
1. Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11.
Shigesada K; van de Sluis B; Liu PP
Oncogene; 2004 May; 23(24):4297-307. PubMed ID: 15156186
[TBL] [Abstract][Full Text] [Related]
2. Core binding factor genes and human leukemia.
Hart SM; Foroni L
Haematologica; 2002 Dec; 87(12):1307-23. PubMed ID: 12495904
[TBL] [Abstract][Full Text] [Related]
3. Altered affinity of CBF beta-SMMHC for Runx1 explains its role in leukemogenesis.
Lukasik SM; Zhang L; Corpora T; Tomanicek S; Li Y; Kundu M; Hartman K; Liu PP; Laue TM; Biltonen RL; Speck NA; Bushweller JH
Nat Struct Biol; 2002 Sep; 9(9):674-9. PubMed ID: 12172539
[TBL] [Abstract][Full Text] [Related]
4. Function of the inv(16) fusion gene CBFB-MYH11.
Kundu M; Liu PP
Curr Opin Hematol; 2001 Jul; 8(4):201-5. PubMed ID: 11561156
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of CBFbeta-SMMHC protein reveals a unique nuclear localization in acute myeloid leukemia with inv(16)(p13q22).
Zhao W; Claxton DF; Medeiros LJ; Lu D; Vadhan-Raj S; Kantarjian HM; Nguyen MH; Bueso-Ramos CE
Am J Surg Pathol; 2006 Nov; 30(11):1436-44. PubMed ID: 17063086
[TBL] [Abstract][Full Text] [Related]
6. Identification of the chimeric protein product of the CBFB-MYH11 fusion gene in inv(16) leukemia cells.
Liu PP; Wijmenga C; Hajra A; Blake TB; Kelley CA; Adelstein RS; Bagg A; Rector J; Cotelingam J; Willman CL; Collins FS
Genes Chromosomes Cancer; 1996 Jun; 16(2):77-87. PubMed ID: 8818654
[TBL] [Abstract][Full Text] [Related]
7. The chimeric protein, PEBP2 beta/CBF beta-SMMHC, disorganizes cytoplasmic stress fibers and inhibits transcriptional activation.
Tanaka Y; Fujii M; Hayashi K; Chiba N; Akaishi T; Shineha R; Nishihira T; Satomi S; Ito Y; Watanabe T; Satake M
Oncogene; 1998 Aug; 17(6):699-708. PubMed ID: 9715271
[TBL] [Abstract][Full Text] [Related]
8. Detection of the CBFB/MYH11 fusion gene in de novo acute myeloid leukemia (AML): a single-institution study of 224 Japanese AML patients.
Monma F; Nishii K; Shiga J; Sugahara H; Lorenzo F; Watanabe Y; Kawakami K; Hosokai N; Yamamori S; Katayama N; Shiku H
Leuk Res; 2007 Apr; 31(4):471-6. PubMed ID: 17052753
[TBL] [Abstract][Full Text] [Related]
9. Core-binding factor: a central player in hematopoiesis and leukemia.
Speck NA; Stacy T; Wang Q; North T; Gu TL; Miller J; Binder M; MarÃn-Padilla M
Cancer Res; 1999 Apr; 59(7 Suppl):1789s-1793s. PubMed ID: 10197598
[TBL] [Abstract][Full Text] [Related]
10. Genomic acute myeloid leukemia-associated inv(16)(p13q22) breakpoints are tightly clustered.
van der Reijden BA; Dauwerse HG; Giles RH; Jagmohan-Changur S; Wijmenga C; Liu PP; Smit B; Wessels HW; Beverstock GC; Jotterand-Bellomo M; Martinet D; Mühlematter D; Lafage-Pochitaloff M; Gabert J; Reiffers J; Bilhou-Nabera C; van Ommen GJ; Hagemeijer A; Breuning MH
Oncogene; 1999 Jan; 18(2):543-50. PubMed ID: 9927211
[TBL] [Abstract][Full Text] [Related]
11. Common gene expression signatures in t(8;21)- and inv(16)-acute myeloid leukaemia.
Ichikawa H; Tanabe K; Mizushima H; Hayashi Y; Mizutani S; Ishii E; Hongo T; Kikuchi A; Satake M
Br J Haematol; 2006 Nov; 135(3):336-47. PubMed ID: 16989659
[TBL] [Abstract][Full Text] [Related]
12. Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice.
Yanagida M; Osato M; Yamashita N; Liqun H; Jacob B; Wu F; Cao X; Nakamura T; Yokomizo T; Takahashi S; Yamamoto M; Shigesada K; Ito Y
Oncogene; 2005 Jun; 24(28):4477-85. PubMed ID: 15856017
[TBL] [Abstract][Full Text] [Related]
13. RUNX1 repression-independent mechanisms of leukemogenesis by fusion genes CBFB-MYH11 and AML1-ETO (RUNX1-RUNX1T1).
Hyde RK; Liu PP
J Cell Biochem; 2010 Aug; 110(5):1039-45. PubMed ID: 20589720
[TBL] [Abstract][Full Text] [Related]
14. Runx1 is required for hematopoietic defects and leukemogenesis in Cbfb-MYH11 knock-in mice.
Hyde RK; Zhao L; Alemu L; Liu PP
Leukemia; 2015 Aug; 29(8):1771-8. PubMed ID: 25742748
[TBL] [Abstract][Full Text] [Related]
15. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.
Osato M
Oncogene; 2004 May; 23(24):4284-96. PubMed ID: 15156185
[TBL] [Abstract][Full Text] [Related]
16. CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16).
Helbling D; Mueller BU; Timchenko NA; Schardt J; Eyer M; Betts DR; Jotterand M; Meyer-Monard S; Fey MF; Pabst T
Blood; 2005 Aug; 106(4):1369-75. PubMed ID: 15855281
[TBL] [Abstract][Full Text] [Related]
17. Core-binding factor beta (CBFbeta), but not CBFbeta-smooth muscle myosin heavy chain, rescues definitive hematopoiesis in CBFbeta-deficient embryonic stem cells.
Miller JD; Stacy T; Liu PP; Speck NA
Blood; 2001 Apr; 97(8):2248-56. PubMed ID: 11290585
[TBL] [Abstract][Full Text] [Related]
18.
Zhen T; Kwon EM; Zhao L; Hsu J; Hyde RK; Lu Y; Alemu L; Speck NA; Liu PP
Blood; 2017 Nov; 130(22):2431-2442. PubMed ID: 29018080
[TBL] [Abstract][Full Text] [Related]
19. Cbfbeta reduces Cbfbeta-SMMHC-associated acute myeloid leukemia in mice.
Heilman SA; Kuo YH; Goudswaard CS; Valk PJ; Castilla LH
Cancer Res; 2006 Dec; 66(23):11214-8. PubMed ID: 17145866
[TBL] [Abstract][Full Text] [Related]
20. Dimerization with PEBP2beta protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation.
Huang G; Shigesada K; Ito K; Wee HJ; Yokomizo T; Ito Y
EMBO J; 2001 Feb; 20(4):723-33. PubMed ID: 11179217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]